The main findings of our study are as follows: (1) In the whole population group, the MACE rate at 9 years was 34.1% (n = 70), MI rate: 11.2% (n = 23), stroke rate: 2.4% (n = 5), and death rate: 20.5% (n = 42); (2) High sclerostin levels were associated with worse prognosis (MACE and death) in the whole study population, in subjects with chronic coronary syndromes, and subjects with low advancement of coronary artery disease (SYNTAX 0–22); (3) The prognosis of subjects with CCS and ACS did not differ significantly at 9-year follow-up. The gene discussed is SOST; the disease is Stroke.